Mucolipidosis IV (MLIV) is an orphan neurodevelopmental disease that causes severe neurologic dysfunction and loss of vision. Currently there is no therapy for MLIV. It is caused by loss of function of the lysosomal channel mucolipin-1, also known as TRPML1. Knockout of the Mcoln1 gene in a mouse model mirrors clinical and neuropathologic signs in humans. Using this model, we previously observed robust activation of microglia and astrocytes in early symptomatic stages of disease. Here we investigate the consequence of mucolipin-1 loss on astrocyte inflammatory activation in vivo and in vitro and apply a pharmacologic approach to restore Mcoln1 À/À astrocyte homeostasis using a clinically approved immunomodulator, fingolimod. We found that Mcoln1 À/À mice over-express numerous pro-inflammatory cytokines, some of which were also over-expressed in astrocyte cultures. Changes in the cytokine profile in Mcoln1 À/À astrocytes are concomitant with changes in phospho-protein signaling, including activation of PI3K/Akt and MAPK pathways. Fingolimod promotes cytokine homeostasis, down-regulates signaling within the PI3K/Akt and MAPK pathways and restores the lysosomal compartment in Mcoln1
Introduction
Mucolipidosis IV (MLIV) is a devastating neurologic childhood disease with a dramatic unmet medical need. At present, there is neither a specific treatment for MLIV nor a complete mechanistic model explaining its pathology. The neurologic symptoms usually appear during the first year of life and result in motor and cognitive deficiencies (1) (2) (3) (4) (5) . Brain magnetic resonance imaging studies have revealed a dysgenic corpus callosum, impaired myelination in the white matter and decreased T2 signal intensities in the thalamus owing to increased ferritin deposition (6, 7) . The vast majority of MLIV patients are of Ashkenazi Jewish origin, with a carrier frequency in this population of about 1:100 (8) . Despite the severity of the disease, human brain pathology data in MLIV are presently limited to two cases (2, 3) . The diagnostic ultrastructural hallmark of MLIV is the accumulation of storage bodies containing gangliosides, phospholipids and acidic mucopolysaccharides reported in every tissue, including the brain (3) . The MLIV gene, MCOLN1, encodes a TRP family ion channel named mucolipin-1, or TRPML1 (9) (10) (11) (12) . There are more than twenty MCOLN1 mutations associated with MLIV (5, 8, 13) . The vast majority of MLIV cases (95% of Ashkenazi Jewish patients) result from a complete loss of mRNA and protein (11, 14) .
The MLIV mouse (Mcoln1
) is an excellent phenotypic model of human MLIV enabling us to interrogate pathways affected by loss of TRPML1. All of the hallmarks of MLIV are present in Mcoln1 À/À mice with the exception of corneal clouding (15) (16) (17) . Defective myelination and gliosis, characteristic of human MLIV, are present in young adult mice at the onset of cognitive and motor deficits (16) . However, activation of microglia and astrocytes was, surprisingly, not accompanied by neuronal loss in the regions with the most pronounced gliosis even at the late stage of disease. At the ultrastructural level, Mcoln1
À/À astrocytes display large electron-dense inclusions with compact membranous and granular compartments that are characteristic of MLIV (16) . Therapy development is especially challenging in MLIV for a number of reasons. Since most MLIV patients do not have MCOLN1 transcripts, chaperone therapy or pharmacologic enhancement of TRPML1 channel function are low-priority treatment approaches for MLIV. Other therapy approaches that are being successfully pursued for enzymatic lysosomal diseases, including infusion of recombinant protein, bone-marrow transplantation or gene-therapy, are based on cross-correction phenomena, and hold low or no promise in MLIV owing to transmembrane localization of TRPML1. Therefore, we believe that identifying and modulating the cellular pathways affected by loss of TRPML1 is a more tractable way to address the MLIV treatment challenge.
Astrocyte activation is a particularly attractive therapeutic target for MLIV since astrocytes are now recognized to play pathogenic roles in numerous neurodegenerative diseases (18, 19) . Moreover, astrocyte activation is a common feature of numerous lysosomal diseases with CNS impairment, including Niemann-Pick disease, neuronal ceroid lipofuscinosis (NCL) and multiple sulfatase deficiency (20) (21) (22) (23) . In juvenile NCL (CLN3 disease), astrocytes are functionally compromised and have been reported to have negative impact on neuronal survival and neurite morphology, demonstrating an active and detrimental role in CNS diseases (23) .
Given that reactive astrocytosis is a key feature of the CNS pathology in MLIV and appears early in the course of the disease, we set out to test whether astrocyte dysfunction is a cell- (Fig. 1E ). Error bars [ Fig. 1E , mean-6 standard deviation (SD)] generated via a leave-one-out crossvalidation (LOOCV) suggest that the involvement of any one cytokine in the profile was not owing to just a single sample (note that in contrast to these LOOCV plots, error bars are presented as mean 6 standard error of mean (SEM) in bar plots used to compare differences between genotypes and conditions). Based on the profile, LV1, we observed significant difference between genotypes (Fig. 1F) . Moreover, the profile identified numerous pro-inflammatory cytokines up-regulated in Mcoln1 À/À mice, including IP-10, IL-17, Eotaxin and KC (Fig. 1G) . These cytokines are known to be secreted by activated astrocytes (27) (28) (29) (30) (31) (32) (33) and to promote microglial activation (28, 29, (34) (35) (36) (37) concentration of 50 nM amyloid b1-42 or 10 ng/ml IL-1b yielded increased production of all cytokines measured (Supplementary Material, Fig. S1 ). This result suggests that loss of TRPML1 produces an isolated change in astrocyte inflammatory activation that is distinct from the activation profile associated with gross pathogenic or pro-inflammatory stimulation. Importantly, certain cytokines up-regulated in and Tables S1 and S2 Importantly, our analysis identified significant up-regulation of inflammatory signaling through IL-6, IL-4 and Interferon-a and -b pathways in Mcoln1 À/À astrocytes, with at least 30% of the detectable genes in these pathways enriched (Fig. 4D) . Upregulation of these pathways is consistent with our cytokine-chemokine and phospho-protein signaling data and further indicates cell-autonomous pro-inflammatory activation of Mcoln1 À/À astrocytes. We also noted significant changes in the sphingosine-1-phosphate (S1P) pathway ( Fig. 4B and D) , which is upstream of multiple pro-inflammatory pathways (Fig. 3A) . Interestingly, multiple pathways related to the metabolism of lipids and carbohydrates were also significantly overrepresented in Mcoln1 À/À astrocytes (Fig. 4B) . GSEA analysis further identified that gene sets for astrocyte markers and aquaporin-mediated transport were also upregulated in chemotactic cytokines. While these cytokines reveal an important mechanism of astrocyte-mediated inflammatory signaling, they do not represent promising therapeutic targets owing to the lack of blood-brain barrier-permeable molecules that directly target cytokines and the non-specificity of such molecules. Importantly, our data also indicate strong up-regulation of multiple phospho-proteins in the MAPK and PI3K/Akt pathways in Mcoln1 À/À astrocytes (Fig. 3 ) and in the S1P pathway (Fig. 4D) , which is up-stream of both of these. These pathways regulate transcription of numerous pro-inflammatory factors, including cytokines. Thus, their broad dysregulation is likely promoting astrocyte inflammatory response and cytokine expression, leading to pro-inflammatory activation of microglia.
Although specific blood-brain barrier permeable signaling inhibitors are available for targeting both MAPK and PI3K/Akt pathways, our observation that the two pro-inflammatory pathways are simultaneously up-regulated suggests that individual pathway suppression may not totally down-regulate cytokine expression. Interestingly, however, both MAPK and PI3K/Akt signaling are downstream of S1P (Fig. 3A ) (24, 45) . Moreover, the pan-S1P receptor inhibitor, fingolimod (FTY720), has recently been approved to treat relapsing multiple sclerosis (46) , and has been shown to down-regulate inflammatory activation of astrocytes (47, 48) . Therefore, we evaluated fingolimod in our astrocyte cultures to determine if it could suppress inflammatory signaling. Indeed, pre-treatment of astrocytes for 1 h with phospho-fingolimod (p-fing, the active form of the drug, 600 nM) significantly reduced MAPK and PI3K/Akt phosphorylation ( Fig. 5A and B (49, 50) . Similarly, we detected increased expression of Lamp1 in our primary astrocytic culture derived from Mcoln1 À/À mice (Fig. 6 ) as expressed by mean fluorescent intensity in GFAP-positive cells. Strikingly, our treatment with p-fingolimod (600 nM for 24 h) was able to significantly suppress the intensity of Lamp1 staining and suggests that fingolimod may potently correct lysosomal function, the primary cell pathology in MLIV.
Discussion
Though lysosomal inclusions are found in all organs and tissues of MLIV patients, CNS and eye dysfunction are the most debilitating aspects of the disease (4,51,52). The Mcoln1 À/À mouse model has provided a detailed view of pathogenesis and suggests that astrocyte, microglial and oligodendrocyte dysfunction precedes neuronal damage. Astrocyte activation promotes pathogenesis in multiple neurodegenerative disease, both via their crosstalk with microglia and their direct neurotoxic effects via reactive oxygen species production and cytokine expression (18, 19, 53, 54) . We hypothesized that astrocyte dysfunction may be a cell-autonomous process in MLIV. Indeed, our data show that cultured Mcoln1 À/À astrocytes possess increased signaling through multiple pro-inflammatory pathways and an abnormal lysosome. Our data also show that cytokines upregulated in the mouse cortex, including IP-10, RANTES and VEGF are secreted by Mcoln1 À/À astrocytes in culture (Figs 1 and 2 ). Incomplete overlap between cytokine/chemokine profiles in the mouse brain homogenates and media conditioned by astrocytes in vitro could be explained by the complexity of the brain tissue, as the chemokines and cytokines are produced by various brain cells, including astrocytes, neurons, microglia, brain endothelial cells and oligodendrocytes. In addition to this, our in vitro system allows us to measure only the factors secreted by the cells, whereas in brain homogenates we asses both intracellular and secreted levels. Interestingly, IP-10, RANTES and VEGF all recruit microglia in several diseases, including Alzheimer's disease (34, 35, 40, (55) (56) (57) (58) . IP-10 is a pro-inflammatory cytokine primarily expressed by astrocytes (30) that triggers pro-inflammatory activation of microglia and may cause enhancement of brain-blood barrier permeability and myelin loss (28, 34, 59) . Therefore, it is likely that astrocytes play a major role in promoting neuroinflammation and microglial activity in MLIV. The success of the immunomodulatory drug fingolimod for treating recurring multiple sclerosis and its recently reported effect of reducing astrogliosis in epilepsy, stroke and multiple sclerosis models (46, 47, 60, 61) , shows its therapeutic potential for targeting neuroinflammation and neuroprotection (62, 63) . Moreover, fingolimod is a strong candidate for treating astrocytes in MLIV because our analysis of inflammation-mediating signaling shows that Mcoln1 À/À astrocytes possess dysregulated signaling both within the S1P gene sets (Fig. 4D ) and in multiple pathways (MAPK and PI3K/Akt), which are downstream of the S1P receptors that fingolimod targets (Fig. 3) . Our finding that fingolimod-phosphate (the biologically active form of fingolimod) was able to suppress signaling in both of these pathways confirms its broad immunomodulatory potency for astrocytes. Fingolimod targets S1P pathway, which is implicated in migration, differentiation, mitogenesis, apoptosis and inflammation (64) . The S1P pathway consists of five G-protein coupled S1P receptors (S1PR1-S1PR5), each of which transduce signaling to different down-stream proteins, including through the PI3K/ Akt and MAPK pathways reported here. Importantly, fingolimod is a functional antagonist of all 5 receptors, and drugs that target only a sub-set of these receptors do not possess immunomodulatory properties (24) . While we have not directly quantified S1P, our transcriptomic analysis found that the S1P pathway was altered in Mcoln1 À/À astrocytes ( Fig. 4B and D) .
This, together with our demonstration that multiple downstream S1P pathways are dysregulated in MLIV, strongly suggests that fingolimod would improve astrocyte function. Interestingly, despite broad suppression of MAPK and PI3K/ Akt signaling, p-fingolimod only modulated some of the inflammatory cytokines over-expressed by Mcoln1 À/À astrocyte cultures (e.g. IP-10, IL-6 and MIP-1b; Fig. 5B ), while others were unchanged (e.g. RANTES, VEGF and MCP-1). Importantly, each of the modulated cytokines or chemokines have strong pro-inflammatory roles, while those that were not affected are primarily chemokines. One of the chemokines resistant to p-fingolimod treatment is a neurotrophic factor VEGF (39) . Lack of its suppression by p-fingolimod in Mcoln1 À/À astrocytes may be an important part of the neuroprotective action of fingolimod.
Although showing only a modest trend in suppressing IP-10 in our data (Fig. 5D ), the effect of fingolimod to suppress IP-10 has been also demonstrated in an in vivo model of traumatic brain injury model and in human primary astrocytes (62, 65) . In addition to inflammatory and signaling differences,
Mcoln1
À/À astrocytes reproduced defective Lamp1 staining of lysosomes (Fig. 6) . Excitingly, p-fingolimod suppressed Lamp1-positive immunoreactivity in Mcoln1 À/À cells, which may suggest a restoration of lysosomal homeostasis. Note that morphologic assessment does not entirely prove the functional recovery of lysosomes in our experiments since we did not perform any functional assessment. The effects of fingolimod on lysosomal function have not previously been reported. However, mTOR is a strong regulator of lysosomal activity (66) . Thus, one possible mechanism for the positive effect of p-fingolimod on lysosomal function is via inhibition of the PI3K/Akt pathway, including mTOR (Fig. 5 ). Mucolipin-1 is known to be a key regulator, and also a target, of mTOR signaling (67) (68) (69) (70) . Therefore, the fact that inhibition of mTOR by p-fingolimod resulted in reversal of the lysosomal phenotype in the absence of mucolipin-1 is intriguing and may indicate unknown mucolipin-1-independent compensatory mechanisms of mTOR regulation of lysosomal function. Since dysfunctional lysosomes are the key pathologic hallmark of MLIV in humans and mice, this result suggests that fingolimod restores homeostasis of multiple functional components affected in MLIV. Fingolimod has been used in 93 clinical trials for multiple sclerosis and other diseases (www.Clinicaltrials.com). It is currently in trials for acute stroke (NCT02002390), astrocytoma (NCT02490930), ALS (NCT01786174), schizophrenia (NCT01779700), Rett syndrome (NCT02061137) and multiple sclerosis (NCT01892722). Importantly, the latter two are pediatric trials. These studies are anticipated to provide extensive safety data for various age groups and extend the list of indications. Given the growing evidence of the role of neuroinflammation in CNS dysfunction and disease (71, 72) , it is likely that fingolimod may prove effective in other rare genetic conditions such as MLIV. A recent study reported that fingolimod was beneficial in mouse models for two forms of NCL, CLN1 and CLN3 (73, 74) . Administration of fingolimod reduced microgliosis and infiltration of T cells into the CNS and attenuated axonal damage and neuronal death in the brain and retina in both models. This exciting result highlights the promise of employing immunomodulation for the treatment of lysosomal diseases, including MLIV. Our future work will be focused on pre-clinical testing of fingolimod in our Mcoln1
À/À mouse model of MLIV, where the effect on astrocyte and microglia activation, levels of brain cytokines and chemokines and other hallmarks of MLIV neuropathology will be measured. In summary, our data show that Mcoln1 À/À astrocytes show broad signaling dysregulation. Moreover, these defects in signaling are associated with elevated expression of proinflammatory cytokines which likely promote MLIV pathogenesis. Excitingly, p-fingolimod was highly effective at restoring intracellular signaling, cytokine secretion and lysosomal function in Mcoln1 À/À astrocytes. Since fingolimod is already FDAapproved for MS, our data suggest it can be a rapidly translatable therapeutic strategy for this devastating childhood disease.
Materials and Methods

Animals
Mcoln1 knock-out mice (on a C57Bl/6J background) were maintained and genotyped as described previously (17) . Mcoln1
and Mcoln1 À/þ mouse pups for astrocytic cultures were gener-
) were used as controls for all experiments. CD-1 mice for the amyloid b1-42 conditioning experiment were purchased from Charles River. All experiments were performed according to the US National Institute of Health guidelines and approved by the Massachusetts General Hospital or the Georgia Institute of Technology Institutional Animal Care and Use Committee.
Astrocyte cultures
Neonatal littermate Mcoln1
À/À and Mcoln1 À/þ , or CD-1, pups (post-natal days 1-3) were euthanized by decapitation and tail snips were collected for genotyping. Brains were harvested, cortices isolated and meninges removed. The cortical tissue was homogenized via trituration and then transferred to poly-L-lysine (PLL) coated T25 cell culture flasks. The next day, flasks were knocked and media was exchanged to remove unwanted debris or residual tissue. Cells were grown to confluency (5-7 days), then placed on a shaker at 250 rpm for 18 h at 37 C to eliminate OPCs and microglia. After shaking the media was aspirated to remove the detached non-astrocytic cells, and the flask was rinsed with phosphate buffered saline (PBS). Astrocytes were detached from the bottom of the flask by trypsin; cells were counted and seeded in cell culture plates. For cytokine/chemokine and phosphoprotein assays, cells were seeded in six-well plates at 120 000 cells per well. Wild-type CD-1 astrocytes were used for analysis of cytokine expression in response to amyloid b1-42 in a vehicle of 0.001% NH 4 OH (rPeptide, Bogart, GA, USA). For immunocytochemistry, cells were seeded on 12 mm PLL-pre-coated glass coverslips in 24-well plates at 30 000 cells per slip. After confluency was established (6-7 days) media was aspirated and replaced with 1 ml per well of either basal culture media or supplemented with 600 nM fingolimod phosphate for either 5 minutes or 24 h. Treatment was quenched with a cold PBS wash, conditioned media was collected, cells were lysed using the Bio-Plex Cell Lysis Kit (Bio-Rad, Hercules, CA, USA), scraped and lysates collected for analysis. For microscopy, cells seeded on glass coverslips were cultured for 6 days and were then treated with 300 ml of either base media or 600 nM fingolimod phosphate for 24 h. Treatment was quenched using cold PBS and slips were fixed in 4% PFA for 10 min on ice. Slips were rinsed and stored in PBS for future staining.
Luminex multiplexed immunoassays for cytokine and phospho-protein detection Partial least squares modeling D-PLSRs were performed in MATLAB using the PLS function written by Cleiton Nunes (available on the MathWorks File Exchange). The data were z-scored before being input into the PLS script. D-PLSRs were run individually for each Luminex assay. Phospho-proteins or cytokine measurements were used as the independent variables, and the discrete regression variable in all analyses was astrocyte treatment condition. Orthogonal rotations were applied to the sample scores and analyte weightings to obtain consistent separation of each group along the LV1 and LV2 axes. Error bars for LV loadings were calculated by iteratively excluding samples without replacement 1000 times, and regenerating the D-PLSR model each time. Error bars in the LV1 plots report the mean and SD computed across the models generated to provide an indication of the variability within each cytokine or phospho-protein among models.
Immunocytochemistry and image analysis
Fixed cells were blocked in 1% BSA (Gibco by ThermoFisher Scientific), 2% normal goat serum (Vector Laboratories, Burlingame, CA, USA) and 0.05% Saponin (Millipore Sigma) in PBS at room temperature for 5 min. Cells were then stained using primary antibodies against GFAP (mouse, 1:1000; 3670S, Cell Signaling Technology, Danvers, MA, USA) and LAMP1 (rat, 1:1000; 553 792; BD Pharmingen, San Jose, CA, USA) in blocking buffer for 90 min at room temperature. Cells were washed three times in 1% BSA in PBS and then stained with secondary antibodies goat anti-mouse AlexaFluor488 (1:1000; Invitrogen, Eugene, OR, USA) and goat anti-ratAlexaFluor633 (1:1000; Invitrogen) for 1 h at room temperature. Cells were again washed and then mounted on glass slides using Immumount (ThermoFisher Scientific). Cells were imaged using a Leica TCS SP5 confocal laser scanning microscope (Leica Microsystems, Inc., Wetzlar, Germany) with a 20Â dry objective. Cells were imaged in Z-stacks with 1 lm intervals and Z-sections with the biggest cell surface area were included in analysis. Images were analyzed using FIJI software (NIH, Bethesda, MD, USA). Selections [region of interests (ROIs)] were made by tracing GFAP positive cells. All present GFAPþ cells within six to seven fields of view per genotype/treatment group were included in analysis. All images were thresholded using the same settings and mean pixel intensity of LAMP1 staining for all GFAPþ cells
measured. Normality of the datasets was analyzed using D'Agostino and Pearson normality test using GraphPad Prizm 7 software (GraphPad, La Jolla, CA, USA). Lamp1 staining was primarily different in distribution, rather than mean, therefore, we compared Lamp1 staining for using the Brown-Forsythe variance test using vartestn in MATLAB.
Immunohistochemistry, imaging and analysis
Brain tissues for histologic analysis were obtained from P1, P10 and 2-month-old Mcoln1 À/À and Mcoln1 þ/þ mice. Brains were fixed in 4% PFA for 24 h, washed with PBS, cryoprotected in 30% sucrose, frozen in isopentane, and stored at À80 C until sectioned. For the P1 and P10 tissues, 20 mm thick coronal sections were made using a Cryostat and directly adhered to glass slides. Slides were allowed to dry completely overnight at room temperature, and sections were outlined with Dako Pen (Agilent, Santa Clara, CA, USA). Antigen retrieval was achieved by microwaving the slides 18 min, low power, in citrate buffer (10 mM citric acid and 0.05% Tween 20, pH 6.0). Slides were washed with PBS and then incubated for 1 h at room temperature with blocking buffer (0.5% Triton X-100, 5% normal goat serum in PBS). Primary anti-GFAP antibodies (mouse, 1:1000; 3670S; Cell Signaling Technology) in 1% NGS in PBS were applied and incubated overnight at 4 C. The next day, slides were incubated with secondary donkey anti-mouse AlexaFluor 488 antibodies (1:500; Invitrogen) for 90 min at room temperature, washed and mounted with Immumount (ThermoFisher Scientific). The brains from 2-month-old mice were serially sectioned at 40 mm thickness and stored free-floating in 96-well plates with TBSAF (TBS, 30% ethylene glycol, 15% sucrose and 0.05% sodium azide) at À80 C. GFAP immunostaining was done according to the protocol above adopted for free-floating sections. The cortex region of each section was imaged on a Leica DMi8 epifluorescent microscope with at 10Â dry objective. Images were the processed using FIJI (NIH). Regions of primary somatosensory and primary and secondary motor cortex were selected on each image, equally thresholded, and GFAP immunoreactivity was measured and expressed as percent of positive pixels from each selection. Comparisons between genotype groups were made using unpaired t-test in GraphPad Prizm 7 software (GraphPad).
RNA isolation and sequencing details
For RNA-seq, astrocyte pellets were collected and stored at -80 C. Total RNA was prepared using an RNeasy mini kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's guidelines, which included DNase treatment. We used a modification of MARSseq (75) for the generation of RNA-seq libraries. RNA-seq libraries were sequenced using Illumina NextSeq-500. Adaptors and low-quality bases were removed from the raw reads by cutadapt (76) and the remaining reads were mapped to the Mus musculus genome (mm10) using STAR v2.4.2a (77) with the option alignEndsType EndToEnd, and only the reads with unique mapping were considered for further analysis. Gene expression levels were calculated using htseq-count (78) with the option intersecsion-strict and mm10 Refseq 3 0 UTR GRF annotations. Normalization and differential expression analysis were performed using the DESeq2 R-package (Bioconductor, https:// bioconductor.org/packages/release/bioc/html/DESeq2.html).
Transcriptome analysis
Genes measured by RNA-seq were normalized using DESeq2 Rpackage and only genes with 10 or more normalized reads for at least one sample were selected for analysis. Differentially expressed genes were defined as genes that had significant adjusted P-value <0.05. GSEA (44, 79) was run using the MLIV astrocyte RNA-seq data and the full curated pathways list version 6.1 (cp2 v6.1 available at software.broadinstitute.org/gsea) with gene-set permutations. As recommended GSEA was conducted using human annotated gene sets. Mouse gene names were converted to upper case nomenclature to match human gene symbols and input to the GSEA software. Pathways above 0.25 FDR were considered significantly enriched (44, 79) . The accompanying heatmaps (generated using MATLAB) show normalized expression values for the genes in our dataset that fall in select enriched pathways.
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